related documents
- A comparison of BRCA1 and BRCA2 risk assessment models. Conferences
- A comparison of patient and physician attributes that promote patient involvement in treatment decision making in the oncology consultation. Conferences
- A phase II study of lapatinib in recurrent or metastatic EGFR and/or ErbB2 expressing adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT). Conferences
- A randomized controlled trial (RCT) of long-term follow-up for early stage breast cancer comparing family physician to specialist care: A report of secondary outcomes. Conferences
- A randomized controlled trial to evaluate the impact of an educational DVD an cancer patients considering participation in a phase I clinical trial. Conferences
- Agreement between physicians and patients about what constitutes shared decision making. Conferences
- Angiagenesis pathway gene polymorphisms associated with clinical outcome in recurrent ovarian cancer treated with low dose cyclophosphamide and bevacizumab: A California Consortium Trial. Conferences
- Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study. Conferences
- Bortezomib is active in Waldenstrom's Macroglobulinemia (WM) - Results of a National Cancer Institute of Canada (NCIC) phase II study in previously untreated or treated WM. Conferences
- Cognitive impairment associated with chemotherapy for breast cancer: An exploratory case-control study. Conferences
- Cytokine levels in patients (pts) with localized colorectal cancer (CRC) after surgery and their relationship to fatigue and cognitive function. Conferences
- Delays in diagnosis and initiating treatment for patients with lung cancer. Conferences
- Direct decompressive surgery with post-operative radiotherapy (S+RT) versus radiotherapy (RT) alone for the treatment of metastatic epidural spinal cord compression (MESCC): A cost-utility analysis using Ontario health economic data. Conferences
- Dose banding of chemotherapy doses at the Juravinski Cancer Centre. Conferences
- Effects of adjuvant chemotherapy on the protein C anticoagulant pathway in patients with early stage breast cancer. Conferences
- Favorable Outcome for Adolescents With Acute Lymphoblastic Leukemia Treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols Conferences
- Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C) plus paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): A study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). Conferences
- Long-term results of concurrent gemcitabine (G) and radiotherapy (GRT) for locally advanced (LA) or high-risk resected (R) pancreatic cancer. Conferences
- Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer - NCICIND 160. Conferences
- NCICCTG MA.17: Tolerability of letrozole among ethnic minority women. Conferences
- Neuroendocrine tumors (NET) of the gastrointestinal tract: A decade of experience at the Princess Margaret Hospital. Conferences
- Optimizing the design and distribution of clinical trial information via handheld devices. Conferences
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia Conferences
- Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP). Conferences
- Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial. Conferences
- Predicting recurrence following post-chemotherapy retroperitoneal lymph node dissection for residual fibrosis or teratoma. Conferences
- Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Conferences
- Quality of life (QOL) of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) following treatment with docetaxel or mitoxantrone in the TAX-327 study. Conferences
- Randomized clinical trials in oncology stopped early for benefit (RCTSEB). Conferences
- Understanding and preferences for receiving prognostic information: A comparison of the views of Australian and Canadian patients with metastatic cancer Conferences